Ireland's Q1 2026 GDP Falls 12.1% Due to US Pharma Export Drop

Ireland's Gross Domestic Product (GDP) fell 12.1% in the first quarter of 2026 compared to the previous three months, as reported by the Central Statistics Office (CSO). This decline, which leaves GDP down 17.1% year-on-year, will impact euro zone GDP figures and highlights the volatility in Ireland's international sector, largely influenced by US President Donald Trump's policies.

The primary reason for the fall was a sharp decrease in high-value pharmaceutical exports from US multinational subsidiaries in Ireland back to the American market. Last year, companies surged shipments to the US to pre-empt potential tariffs from the Trump administration. As most pharmaceutical exports to the US remained tariff-free, shipments have since normalized and fallen this year.

This GDP data, alongside new US rules requiring country-by-country tax reporting, intensifies scrutiny on how these companies utilize Irish subsidiaries to reduce global tax liabilities and the extent of their operations in Ireland. The Trump administration has previously noted Ireland's role in pharma production for the US market, and new US tax incentives and private deals are drawing investment to American states, posing potential threats to Ireland's pharma sector.

Despite these challenges, the CSO figures indicate continued growth in Ireland's domestic economy. However, recent CSO unemployment figures show an increase last month, and parts of the jobs market face difficulties, requiring close monitoring. Ireland's economic resilience may face further tests this year, particularly given the opaque nature of multinational activity within the economy.